Establishment Labs to Present at Jefferies London Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies 2025 London Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, November 19, 2025 at 8:30 a.m. GMT. A live webcast of the.

Business Wire • Nov 7, 2025

Establishment Labs Holdings Inc. (ESTA) Q3 2025 Earnings Call Transcript

Establishment Labs Holdings Inc. ( ESTA ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Rajbir Denhoy - Chief Financial Officer Filippo Caldini - CEO & Director Conference Call Participants Anthony Petrone - Mizuho Americas LLC Joshua Jennings - TD Cowen, Research Division K. Gong - JPMorgan Chase & Co, Research Division Sam Eiber - BTIG, LLC, Research Division Mason Carrico - Stephens Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division Presentation Operator Good afternoon.

Seeking Alpha • Nov 5, 2025

Establishment Labs Reports Third Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2025. Third Quarter Highlights and Outlook (Unaudited) Third quarter worldwide revenue of $53.8 million, an increase of 33.8% from the year ago period. Revenue included $11.9 million of Motiva sales in the.

Business Wire • Nov 5, 2025

Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Beats Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.59 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Establishment Labs to Announce Third Quarter 2025 Financial Results on November 5

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.

Business Wire • Oct 22, 2025

Establishment Labs Notes Publication of Mia Femtech 3-Year Prospective Study Results in Aesthetic Surgery Journal

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the publication of “The 3-Year Results of a 100-Patient Prospective Study of Safety and Effectiveness of Mia Femtech” in the Aesthetic Surgery Journal. The study showed a very low rate of complications, with no reports of capsular contracture (Baker Grade III/IV), implant rup.

Business Wire • Oct 14, 2025

Establishment Labs Publishes 15 Years of Motiva Data in 2025 Post-Market Surveillance Report

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. “Publishing our PMS report every year since the launch of Motiva in 2010 s.

Business Wire • Oct 9, 2025

Establishment Labs Holdings Inc. (ESTA) Q2 2025 Earnings Call Transcript

Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Fillipo Peter Caldini - CEO & Director Rajbir Singh Denhoy - Chief Financial Officer Conference Call Participants Anthony Charles Petrone - Mizuho Americas LLC Joshua Thomas Jennings - TD Cowen, Research Division K. Gong - JPMorgan Chase & Co, Research Division Mason Owen Carrico - Stephens Inc., Research Division Matthew Charles Taylor - UBS Investment Bank, Research Division Mike Matson - Unidentified Company Sam Shimon Eiber - BTIG, LLC, Research Division Operator Good morning.

Seeking Alpha • Aug 8, 2025

Establishment Labs Reports Second Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the Un.

Business Wire • Aug 7, 2025

Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Misses Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.62 per share a year ago.

Zacks Investment Research • Aug 7, 2025